$4.8 Billion

Spark Therapeutics

Sell-side

Financial Advisor, February 2019

Spark Therapeutics
Sale to Roche

Spark is a leader in the field of gene therapy, seeking to transform the lives of patients suffering from debilitating genetic diseases by developing one-time, life-altering treatments. The goal of gene therapy is to overcome the effects of a malfunctioning, disease-causing gene. The Company's product candidates have the potential to provide long-lasting effects, dramatically and positively changing the lives of patients with conditions where no, or only palliative, therapies exist. Spark's initial focus is on treating orphan diseases and the Company has built a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases

More Like This

Jul 2023

Sold Majority Stake in hg medical to Astorg Mid-Cap

Exclusive Financial Advisor

View Details >
May 2023
Jounce Therapeutics Logo

Acquired by Concentra Biosciences

Exclusive Financial Advisor

View Details >
Mar 2023

Smile Source, a Portfolio Company of Brazos Private Equity Partners, has Partnered with Incline Equity Partners

Exclusive Financial Advisor

View Details >